The Role of Biomarkers and Biopsy for IPF and PPF
Anna Podolanczuk, M.D., M.S., discusses how biomarker testing plays a role in diagnosing idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF), helping to distinguish these diseases from other respiratory conditions, as well as the role of biopsy and the histopathological features commonly seen in these diseases.
Video content above is prompted by the following:
- What is the role of biomarker testing in IPF and PPF, and can it be used to distinguish these from other respiratory diseases?
- What is the role of biopsy in identifying patients with IPF and PPF, and what is commonly seen on histopathology?
Examining Health Equity Among Different Racial and Ethnic Subpopulations With Multiple Sclerosis
March 15th 2021Multiple sclerosis (MS) is a chronic disease that involves demyelination of plaque throughout the white and gray matter of the central nervous system. The early stages of MS are usually marked by a relapsing-remitting course of neurological deficits, which progress toward continuous, permanent dysfunction and disability. Of those with a diagnosis of MS, 74% are women.
Read More
Improving Ophthalmic Care Access and Treatment Among Aging Adults
August 20th 2020As the American population ages, chronic conditions are becoming an increasing challenge for payers. In addition to conditions such as cardiovascular disease and diabetes, eye disease is also prevalent among aging adults.
Read More
